Anaheim Bio launches €40 million Series A funding to advance ANA-1 for Calcium Pyrophosphate Deposition Disease into the Clinic

Summary

Anaheim spun out of Alesta Therapeutics before its recent acquisition by BioMarin Financing provided by Droia Ventures, Frazier Life Sciences, RTW, Novartis Venture Fund, RV Invest and Thuja Capital Runway into...